Product
NY-ESO-1 Vaccine
1 clinical trial
3 indications
Indication
Ovarian CancerIndication
fallopian tubeIndication
Primary Peritoneal CancerClinical trial
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine or NY-ESO-1 Overlapping Peptides Vaccine in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater RemissionStatus: Completed, Estimated PCD: 2023-04-06